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Aim. To investigate the characteristics of Emergency Department (ED) presentations due to acute paracetamol intoxication.
Methods. Retrospective observational study of patients presenting to the ED of Bern University Hospital between May 1, 2012,
and October 31, 2018, due to a paracetamol overdose (deﬁned as intake of >4 g/24 h). Cases were identiﬁed using the full-text
search of the electronic patient database and were grouped into intentional (suicidal/parasuicidal) and unintentional in-
toxications (e.g., patient unaware of maximal daily dose). Results. During the study period, 181 cases were included and 143
(79%) of those were intentional. Compared to the patients in the unintentional group, patients in the intentional group were
more often female (85% vs 45%, p< 0.001) and younger (median age 23.0 vs 43.5 years, p< 0.001), more frequently suﬀered
from psychiatric comorbidities (93%, (including 49% with borderline personality disorder) vs 24%, p< 0.001), and paracetamol
was more often taken as a single dose (80% vs 13%, p< 0.001). Although the median daily ingested dose was lower in the
unintentional than in the intentional group (8.2 g vs 12.9 g, p< 0.001), patients in the unintentional group presented later (29%
vs 84% within 24 h of ingestion, p< 0.001), included more cases of acute liver failure (nine (24%) vs six (4%), p< 0.001), and
were more often hospitalised (24% vs 52% treated as outpatients, p � 0.002). $ere were no signiﬁcant diﬀerences between the
groups regarding drug-induced liver injury (seven cases (5%) in the intentional and one (3%) in the unintentional group) or
fatalities (one in each group). Conclusions. $e majority of presentations due to paracetamol poisoning were intentional, most
commonly in female patients with borderline personality disorder. Patients with unintentional paracetamol intoxication had
worse outcomes with respect to acute liver failure and hospitalisation. Future preventive measures should raise awareness of
paracetamol toxicity in the general population and encourage particular attention and frequent follow-ups when prescribing
paracetamol for vulnerable groups.
1. Introduction
Paracetamol (also known as acetaminophen, N-acetyl-p-
aminophenol, and abbreviated as APAP) is a centrally acting
analgesic and antipyretic agent with minimal anti-in-
ﬂammatory properties [1]. It was ﬁrst introduced to the
market in the 1950s [2] and has since become the most
commonly used drug worldwide for the treatment of pain
and fever [2, 3]. Paracetamol is often the agent of choice in
children, due to the well-known adverse eﬀects of alterna-
tives (e.g., Reye syndrome after intake of aspirin [4]). Par-
acetamol may be associated with neurodevelopmental and
behavioural disorders such as attention deﬁcit hyperactivity
disorder (ADHD), and there are ongoing studies on whether
it is linked to an increase in the incidence of asthma in
children [3]. Nevertheless, paracetamol has been the rec-
ommended analgesic drug during pregnancy and breast-
feeding for decades [2]. In most countries, paracetamol is
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available without a prescription as an over-the-counter
(OTC) drug and is generally considered safe if used at the
recommended dosage (i.e., ≤4 g per day in adults [5]).
$e ﬁrst reports of adverse hepatotoxic eﬀects and fatal
outcomes after paracetamol overdose can be found even in
the 1970s [6]. Paracetamol’s hepatotoxicity is generally
considered to be associated with its highly reactive metab-
olite N-acetyl-para-benzoquinone imine (NAPQI), which
can lead to hepatocyte damage [5]. Reported risk factors for
the development of hepatotoxicity include chronic alcohol
ingestion, chronic malnutrition, advanced age, genetic
factors, and comedication with drugs that induce hepatic
cytochrome P450 (CYP) [5, 6]. $e management of para-
cetamol poisoning depends on the mode of intake. After a
single ingestion, paracetamol concentration in serum
(performed at least four hours after ingestion, i.e., after
complete absorption of the drug) can be evaluated using the
Rumack–Matthew nomogram, and the decision about
therapy with N-acetylcysteine (NAC) is then based on the
nomogram’s treatment line [7]. However, this nomogram
cannot be used after staggered intakes of paracetamol in
overdose [8].
Beside unintentional overdoses, paracetamol is often
involved in suicidal attempts. In the United States of
America (USA), intentional overdoses, i.e., suicidal/para-
suicidal behaviour, contribute to about 74–92% of all par-
acetamol overdoses [9]. In the United Kingdom (UK), the
corresponding ﬁgure is ca. 75% [10, 11]. Although fatalities
associated with paracetamol are rather rare in Switzerland
[6], the number of intoxications caused by paracetamol
overdoses increased more than twofold between 1995 and
2016 [12], and over 50% of those cases were intentional
(suicidal) [6].
$e present study was planned to establish the preva-
lence, patterns, and susceptible groups of paracetamol in-
toxications. It covers a period of six and a half years and
describes the frequency, characteristics, and management of
presentations related to paracetamol intoxication at an
Emergency Department (ED) in Bern, Switzerland. $e
results could have major implications for epidemiology and
public health.
2. Materials and Methods
$is retrospective observational study included all patients≥16 years of age presenting to the ED of the University
Hospital Bern between May 1, 2012, and October 31, 2018,
due to paracetamol overdose (deﬁned as intake of >4 g/24 h).
$e ED of Bern University Hospital is both a primary care
facility (walk-in patients) and tertiary referral center for
hospitals in the greater Bern area, with about 48000
emergency admissions a year (2018). $e study was ap-
proved by the local ethics committees (No. BE 2018-02275).
Cases were identiﬁed by using a search function of our
electronic ED patient database E.care (E.care BVBA, ED
2.1.3.0, Turnhout, Belgium). $is medical database allows
recall of past diagnostic reports, consultations, and other
relevant medical documents. A full-text search was per-
formed with “paracetamol” as search term in the diagnosis
ﬁeld of the ED report. $e retrieved cases were then
reviewed, and the cases were selected where the reason of
presentation was (suspected) paracetamol intoxication.
Cases were then excluded if the patient had not given general
consent to process his or hers medical data for research
purposes. In the ﬁnal step, we selected only those patients
with paracetamol overdose deﬁned as intake of more than
4 g paracetamol in 24 h, as based on information given by
patients, patient’s families/friends, or paramedics. We also
included cases in which no exact information was available
about the ingested dose, but the paracetamol level in serum
was above the therapeutic concentration, deﬁned as a
maximum of 32 μg/mL (� 212 μmol/L) [6, 13]. We excluded
cases with no available information about the ingested dose
and serum paracetamol level not above the therapeutic
concentrations. For patients presenting to the ED more than
once due to paracetamol intoxication during the study
period, each individual presentation was considered one
case.
$e following parameters were extracted (if available)
from the charts of the included patients: age, sex, nationality,
circumstances of exposure (i.e., accidental or intentional/
suicide), paracetamol dose, paracetamol level in serum, date
of presentation, reasons for intake, simultaneous intake of
other substances, mode of intake (single vs. increased intake
over several days), latency from ﬁrst intake to presentation,
risk factors, psychiatric comorbidities, laboratory ﬁndings,
treatment provided, type of discharge from the ED (e.g.,
inpatient admission and outpatient therapy), and outcome
(e.g., complications and death).
In terms of outcome, drug-induced liver injury (DILI)
was deﬁned as an elevation of alanine aminotransferase
(ALT) over 5x the upper limit of normal (i.e., >175 IU/L), or
elevation of alkaline phosphatase (ALP) over 2x the upper
limit of normal (i.e., >210 IU/L), or elevation of ALTover 3x
the upper limit of normal (i.e., >105 IU/L) and simultaneous
elevation of bilirubin over 2x the upper limit of normal (i.e.,>34 μmol/L) [14]. Acute liver failure (ALF) as an extreme
form of DILI was deﬁned as elevation of transaminases over
10x the upper limit of normal (i.e., >350 IU/L) with elevation
of INR over 1.5 and an altered level of mental status de-
veloping in less than 26 weeks in patients without preexisting
liver disease [15, 16].
Cases were grouped into intentional (i.e., suicidal or
parasuicidal attempts) and unintentional (e.g., the patients
did not know or ignored the maximal allowed daily dose
because of lack of understanding of overdose-related risks).
Diﬀerences between the two groups were tested using the
chi-squared or Fisher’s exact test for categorical variables,
the t test for normally distributed continuous variables, and
the Mann–Whitney test for nonparametric variables
(p< 0.05 was considered statistically signiﬁcant). Statistical
analyses were conducted using SPSS statistical software
(IBM SPSS Statistics 25.0).
3. Results
A total of 987 potential cases with the word “paracetamol” in
the diagnosis ﬁeld of the ED were retrieved in the ﬁrst step of
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our search. From this group, 214 cases were selected in which
the reason for current presentation was (suspected) para-
cetamol intoxication. Eighteen cases had to be excluded
because of lack of general consent, and 15 further cases did
not fulﬁll the inclusion criteria (e.g., paracetamol intake of<4 g/24 h, no available information about the ingested dose,
and serum paracetamol level not above the therapeutic
concentrations (six cases)) and were also excluded. One
hundred and eighty-one (181) cases of paracetamol in-
toxication were included in the ﬁnal analysis (among them
ﬁve cases without exact information about the ingested dose
available, but paracetamol level in serum above the thera-
peutic concentration), including 38 (21%) unintentional and
143 (79%) intentional overdoses. $ere were no cases of
simultaneous use of diﬀerent paracetamol preparations and
only two cases involving a paracetamol combination product
containing tramadol and paracetamol.
Figure 1 shows the annual distribution of paracetamol
intoxication cases over the study period; intentional and
unintentional cases are illustrated separately in addition to
all cases.
An overview of the main characteristics of the para-
cetamol intoxication cases is provided in Table 1.
3.1. Intentional Paracetamol Intoxication (n� 143).
Among the 143 cases of intentional paracetamol overdoses,
the median age was 23.0 (range 16–85) years, with a pre-
dominance of women (n� 121, 85%), and in 17% of the cases
(n� 24), the nationality of the patients was not Swiss (Ta-
ble 1). Most patients in this group had suicidal intention (134
cases, 94%), while nine (6%) reported no strict suicidal
intention but intention to harm themselves by taking a
paracetamol overdose. $e median daily paracetamol dose
ingested was 12.9 g; the maximal paracetamol dose 90 g
(Table 1). In ﬁve cases, the dose of paracetamol was not
known. $e most common mode of paracetamol intake was
ingestion as a single dose (80%, 115 cases) (Table 1); in 19
cases (13%), paracetamol intake was staggered, and in nine
cases (6%), the mode of intake was not known. Most patients
(120 cases, 84%) presented to the ED during the ﬁrst 24 h
after ﬁrst paracetamol ingestion (Table 1). Twenty-two (22)
patients (15%) presented more than 24 h after the ﬁrst in-
gestion (longest interval between ﬁrst ingestion and pre-
sentation: four days), and in one case, the time from
ingestion to presentation was unknown. In 50% of the in-
tentional cases (n� 72), other substances were taken to-
gether with paracetamol. $e most common agents in those
cases were psychotropic drugs (35 cases) and other anal-
gesics (32 cases), followed by alcohol (19 cases). $ere were
32 cases with ingestion of three or more diﬀerent substances.
In 102 cases (71%), treatment included i.v. NAC, combined
with activated charcoal in 23 (16%) cases with early pre-
sentation. $ree patients (2%) were treated solely with
charcoal, and 15 patients (11%) received no medical therapy.
In 52% of the cases (n� 75), the patients were treated as
outpatients; 6% (9 cases) were treated in a normal hospital
unit, and 59 patients (41%) needed an intensive or in-
termediate care unit. Psychiatric comorbidities were known/
documented in 133 cases (93%) (Table 1). Of these, the most
common was borderline personality disorder (65 cases;
49%), followed by depressive disorder (44 cases; 33%).
Among the borderline patients, four female patients pre-
sented more than four times due to paracetamol intoxication
during the study period (max. number of presentations of
the same patient: 12 times). Other psychiatric comorbidities
were acute psychological crisis/depressive adjustment dis-
order (15 cases, 11%), schizophrenia (5 cases; 4%), addiction
disease (2 cases; 2%), and single cases of patients with eating
disorder and dementia. $ere were six cases of ALF in this
group (4%): two in patients with chronic alcohol intake, one
in a patient with malnutrition, and three without known risk
factors. $e median paracetamol dose taken by patients with
ALF was 26 g (range 21–80 g). $ere were also seven cases of
DILI (5%): two with malnutrition as a risk factor and ﬁve
without risk factors. $e median paracetamol dose taken by
patients with DILI in this group was 35 g (range 15–90 g).
$e paracetamol level in serum was available in 137 (96%) of
the intentional intoxication cases (exact time of measure-
ment in most cases not known). Among these, the con-
centration was in the therapeutic range (i.e., <212 μmol/L) in
39 cases and above the therapeutic range in 98 cases (median
476 μmol/L, range 232–10236.6 μmol/L). $ere was one fatal
case of a 42-year-old female patient with a borderline
personality disorder and intake of multiple drugs (meta-
mizole, diclofenac, and ibuprofen), together with 24 g of
paracetamol. NAC was started in this patient about ﬁve
hours after paracetamol ingestion and was administered
over 20 hours. Although the initially elevated liver enzymes
recovered during hospitalisation, the patient died because of
pneumonia and respiratory insuﬃciency after multiple is-
chemic strokes.
3.2. Unintentional Paracetamol Intoxication (n� 38).
Among the 38 cases of unintentional paracetamol in-
toxication, themedian age was 43.5 (range 16–79) years; 45%
of the patients were women (17 women; 21 men), and 26%
(ten cases) were of non-Swiss nationality (Table 1). $e most
commonly reported reason for paracetamol intake was pain
(35 cases, 92%), followed by common ﬂu symptoms/fever
(three cases, 8%). Patients with pain most commonly re-
ported headache (13 cases), followed by abdominal pain
(nine cases), toothache (six cases), local postoperative pain
(three cases), and throat and back pain (two cases each). $e
maximal dose of ingested paracetamol was 25 g/24 h. $e
median dose per day was 8.2 g (range 5–25) (Table 1). In
most cases (33 cases, 87%), the increased intake took place
over many days because of insuﬃcient pain relief and
without respecting the maximum recommended daily dose,
and most of the patients (27 cases, 71%) presented to the ED
later than 24 h after ﬁrst ingestion of paracetamol in over-
dose. $e longest interval between ﬁrst paracetamol in-
gestion and ED presentation was 21 days. In ten (26%) of the
cases, the patients had also ingested substances other than
paracetamol. $e most commonly reported co-ingested
substances in those cases were other analgesics (i.e., non-
steroidal anti-inﬂammatory drugs (NSAID) or metamizole)
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in six cases and alcohol (six cases). Psychiatric comorbidities
were known/reported in 24% of the cases (n� 9). As regards
treatment, most patients received i.v. NAC (30 cases, 79%).
Due to the long latency from the ﬁrst ingestion to pre-
sentation in most cases, activated charcoal was administered
in only one of the cases receiving NAC. Seven patients (18%)
who presented with normal liver enzymes and latency be-
tween presentation and paracetamol intake of more than one
day received no treatment. Most patients were treated in a
normal hospital unit (16 cases, 42%); 13 (34%) needed an
intensive or intermediate care unit, and nine (24%) were
treated as outpatients (Table 1). $e most common psy-
chiatric comorbidity was depressive disorder (four cases),
followed by addiction disease (three cases) and borderline
personality disorder (two cases). $ere were nine cases of
ALF in this group (Table 1); six of them occurred in patients
with preexisting risk factors (chronic alcohol intake (four
cases), preexisting liver disease (one case) or malnutrition
(one case)). In the ALF subgroup, the median dose of
paracetamol was 8 g per day (range 5.5–15 g); however, the
intake was commonly repeated over many days (eight of the
nine patients with ALF). $ere was one case of DILI after
intake of 15 g paracetamol as a single dose in a patient
without risk factors and one fatal case due to progressive
liver failure in a 64-year-old male patient with preexisting
alcoholic liver cirrhosis, who consumed 9 g paracetamol in
24 h (NAC administered ﬁve days after paracetamol intake
in this case). $e paracetamol level in serum was measured
in 30 (79%) of the cases of unintentional intoxication (exact
time of measurement not documented in most cases).
Among these, the concentration was in the therapeutic range
(i.e., <212 μmol/L) in 21 cases and above the therapeutic
range in 9 cases (median 682 μmol/L, range
330–1723.6 μmol/L).
4. Discussion
In this retrospective study, at a large ED in Switzerland, there
were approximately two presentations/month due to acute
paracetamol overdose during the six and a half years in-
vestigated, with intentional intoxications forming the large
majority (four out of ﬁve cases). Compared to the un-
intentional group, patients with intentional overdose were
more often female, consumed higher single doses of para-
cetamol, and hadmore psychiatric comorbidities. Patients in
the unintentional group were signiﬁcantly older than the
intentional group, presented later to the ED, and although
the dose consumed was lower, the increased intake was more
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Figure 1: Annual distribution of presentations due to paracetamol intoxication (N� 181).
Table 1: Main characteristics of cases presenting due to paracetamol intoxication.
All (N� 181) Intentional (n� 143) Unintentional (n� 38) p
Age in years 25.0 (16–85) 23.0 (16–85) 43.5 (16–79) <0.001
Women 138 (76) 121 (85) 17 (45) <0.001
Swiss citizens 147 (81) 119 (83) 28 (74) 0.18
Paracetamol g/24 h 10.8 (5–90) 12.9 (5–90) 8.2 (5–25) <0.001
Intake as a single dose 120 (66) 115 (80) 5 (13) <0.001<24 h between ingestion and presentation 131(72) 120 (84) 11 (29) <0.001
Intake of paracetamol only 99 (55) 71 (50) 28 (74) 0.008
Psychiatric comorbidities 142 (78) 133 (93) 9 (24) <0.001
DILI 8 (4) 7 (5) 1 (3) 0.54
ALF 15 (8) 6 (4) 9 (24) <0.001
Death 2 (1) 1 (<1) 1 (3) 0.30
Treatment as outpatients 84 (46) 75 (52) 9 (24) 0.002
Time of hospitalisation in days£ 2.0 (1–21) 2.0 (1–21) 2.0 (1–15) 0.001
£Time of hospitalisation not known in ten cases with admission to another hospital. Values are expressed as median (range) or n (%); bold numbers indicate
signiﬁcant diﬀerences (p< 0.05) between the intentional and unintentional groups.
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commonly repeated over many days. $e unintentional
group was also hospitalised more often and for longer
duration and had signiﬁcantly more ALF cases than the
intentional group, while no signiﬁcant diﬀerences between
the groups were found for DILI and fatal outcomes.
Most of our patients with intentional paracetamol
poisoning were female, which is in line with data from the
general suicide statistics from Switzerland, according to
which most suicidal attempts in women are by poisoning
[17]. Data available from Switzerland show the increasing
share of analgesics—particularly paracetamol [12]—as drugs
chosen in suicidal attempts at self-poisoning [18]. According
to the report on suicide patterns in the Bern agglomeration,
analgesics were the second most common drug class after
antidepressants that was involved in suicidal attempts [18].
According to studies from other countries, paracetamol is
one of the most common drugs used in self-harm attempts
[19–21], particularly among females and persons under 25
years [20]. Our results also support the ﬁndings from the UK
and USA where intentional paracetamol intoxications ac-
count for more than 75% of all paracetamol poisonings
[9, 11].
$ese ﬁndings havemajor public health implications and
raise the question about the need for prophylactic measures,
such as restricting availability of paracetamol, although this
can diﬀer between countries. In Switzerland, paracetamol
can be bought as an OTC drug, but is only available in
pharmacies or drug stores. In OTC formulations, the
maximal paracetamol dose per pill is 500mg (750mg in
rectal suppositories) and the maximal paracetamol pack
contains 10 g (12 g as suppositories) [22]. However, with a
physician’s prescription, larger amounts of paracetamol can
be purchased. $ere is a clear link between availability of
paracetamol and the rate at which it is used for suicide
[19, 23]. Some studies suggest that the availability of par-
acetamol through nonpharmacy outlets rather than pack size
is the main factor contributing to the number of paracetamol
poisonings [23]. $is is supported by the ﬁnding that reg-
ulations restricting the pack size of paracetamol available in
a single purchase did not seem to be very eﬀective in the long
term in the UK [24]. However, factors other than pack size
and availability might also aﬀect the rate of suicide attempts,
as also illustrated by the short-term increase in paracetamol
overdoses after depicting such an event in an episode of a
popular medical television drama [25]. $is all tends to
highlight the complexity of the underlying mechanisms and
the diﬃculty of taking timely and appropriate measures. In
contrast to data from the USA [26], overdoses involving
opioid-paracetamol combination products in pain patients
do not seem to be a common problem in our population,
since there were only two cases involving a compound
paracetamol-product (combination of paracetamol and
tramadol) and no cases involving multiple products con-
taining paracetamol.
Cases of unintentional paracetamol overdose were rel-
atively rare in our study. However, this group had a sig-
niﬁcantly higher rate of adverse outcomes in the form of
ALF than the intentional group. In the unintentional group,
most patients had taken paracetamol over many days in
supratherapeutic doses and the presentation to the ED was
often delayed. Together with the greater age of these patients,
this might have contributed to the worse outcomes. $ese
ﬁndings correlate with other studies that found a worse
prognosis of unintentional paracetamol poisonings com-
pared to patients with a single dose intake [11]. $is was due
to mainly staggered intake over many days, postponed
presentation, and late beginning of antidote therapy [27].
$ose cases should be managed with particular care, since
paracetamol serum level and dose ingested per day, which
are the usual evaluation tools of paracetamol intoxication in
the ED, are often much lower than with the intentional cases,
and this might lead to underestimating the high risk of
adverse outcomes. $erapeutic measures—such as very
liberal NAC administration—could help improve treatment
and outcome in this critical group with less clear manage-
ment and worse outcome. As regards prophylactic measures,
unintentional poisoning cases might be avoided if contact to
a primary care doctor is established in order to be able to
provide in depth information about paracetamol toxicity
and to schedule follow-ups to adjust the analgesic therapy as
required (most cases in this group were pain patients, who
performed self-medication with paracetamol and used
supratherapeutic doses due to insuﬃcient pain relief ). $is
highlights the important role of family doctors and general
practitioners, since they can provide more adequate long-
term outpatient care compared to the treatment in the ED
setting.
Psychiatric comorbidities were common in our study
population, particularly in the intentional group. $e most
common psychiatric condition was borderline personality
disorder, followed by depressive disorder. According to a
recent study [28], patients who overdose paracetamol (in-
tentionally as well as unintentionally) display a higher rate of
depression, mismanagement of problematic chronic pain,
frequent substance abuse, and increased impulsivity com-
pared to the general population. On the basis of our ﬁndings,
particular attention should be given to borderline female
patients, as they seem to be at high risk of representing due
to paracetamol intoxication shortly after discharge or while
being hospitalised in a psychiatric unit. Frequent and in-
tensive follow-up in these cases could help to avoid reoc-
currence of suicide attempts.
In our study, there were two deaths after paracetamol
intoxication, of which only one was directly related to
paracetamol overdose. $ere were no cases of liver damage
requiring liver transplantation and cases of ALF were rel-
atively rare, particularly in the intentional group. $e ab-
solute number of adverse outcomes as a result of
paracetamol overdose is lower in Switzerland [6] than in
countries where paracetamol is available in nonpharmacy
outlets. Examples are the USA and UK, where 458 [9] and
100–200 [29] deaths, respectively, occur each year due to
paracetamol-associated overdoses, and paracetamol poi-
soning is the leading etiology of acute liver failure [26]. On
the other hand, numbers per population should also be taken
into consideration for comparisons. According to reports
from the Scottish Liver Transplantation Unit [30], ap-
proximately 50% of the patients admitted with paracetamol-
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induced acute liver injury between December 1992 and
March 2001 developed ALF. However, since approximately
50% of the patients die at home or are not referred to the
Liver Transplantation Unit, based on a population of 4.99
million, the authors assume an incidence of 0.84 per 100000
for Scotland in 2001 (21 admissions) [30]. $us, next to
restriction of paracetamol availability, presence of risk
factors, late presentation and postponed begin of antidote
therapy, demographic diﬀerences, and referral procedures
can also aﬀect the frequency of paracetamol-related adverse
events such as ALF.
Limitations of our study include the retrospective design
and reporting bias (especially in cases of psychiatric
comorbidities). Furthermore, 18 cases could not be included
due to the lack of a general consent form, and parameters
such as psychiatric comorbidities might be overrepresented
in the intentional group due to patients presenting more
than once. Moreover, ten cases were admitted to another
hospital. Although these patients were stable at the time of
admission, no information about the long-term outcome
was available, and data from one ED may not be repre-
sentative for the whole country. $e strengths of the study
include the sensitive search and the manual review of all
cases. To our knowledge, this is the ﬁrst study that has
investigated the characteristics and susceptible groups of
acute paracetamol intoxication in ED presentations in this
population and contributes data to guide public health
measures and to improve patient treatment.
5. Conclusions
On the basis of the ﬁndings of our study, ED presentations
due to paracetamol intoxication are not uncommon. $e
majority of the cases constitute intentional, i.e., suicidal
and parasuicidal, poisonings, often in patients with psy-
chiatric comorbidities (mainly borderline personality
disorder and depression) and with a high recurrence rate
among female borderline patients. Special attention
should be given to patients after unintentional para-
cetamol intoxication, as they make up a vulnerable group
with worse outcome in terms of complications such as
ALF—probably due to prolonged intake and delayed
presentation. Preventive measures should be considered
in order to increase awareness of paracetamol toxicity in
the general population.
Data Availability
$e descriptive data used to support the ﬁndings of this
study are included within the article.
Conflicts of Interest
$e authors declare that there are no conﬂicts of interest
regarding the publication of this article.
Acknowledgments
We thank Rodney Yeates for the editorial assistance.
References
[1] K. Toussaint, X. C. Yang, M. A. Zielinski et al., “What do we
(not) know about how paracetamol (acetaminophen)
works?,” Journal of Clinical Pharmacy and 1erapeutics,
vol. 35, no. 6, pp. 617–638, 2010.
[2] K. Brune, B. Renner, and G. Tiegs, “Acetaminophen/para-
cetamol: a history of errors, failures and false decisions,”
European Journal of Pain, vol. 19, no. 7, pp. 953–965, 2015.
[3] G. Tiegs, K. Karimi, K. Brune, and P. Arck, “New problems
arising from old drugs: second-generation eﬀects of acet-
aminophen,” Expert Review of Clinical Pharmacology, vol. 7,
no. 5, pp. 655–662, 2014.
[4] L. F. Prescott, “Paracetamol,” American Journal of 1era-
peutics, vol. 7, no. 2, pp. 143–148, 2000.
[5] E. Yoon, A. Babar, M. Choudhary, M. Kutner, and
N. Pyrsopoulos, “Acetaminophen-induced hepatotoxicity: a
comprehensive update,” Journal of Clinical and Translational
Hepatology, vol. 4, no. 2, pp. 131–142, 2016.
[6] K. Faber, C. Rauber-Lu¨thy, H. Kupferschmidt, and A. Ceschi,
“Akute Paracetamol-Intoxikation. Klinik, Diagnostik und
$erapie,” Schweizerisches Medizin-Forum, vol. 10, no. 38,
pp. 647–651, 2010.
[7] K. Faber, C. Reichert, and C. Rauber-Lu¨thy, Akute Para-
cetamolvergiftung, Tox Info Suisse, Zu¨rich, Switzerland, 2017.
[8] K. Faber, C. Reichert, and C. Rauber-Lu¨thy, Para-
cetamolvergiftung: Wiederholte Einnahme, Tox Info Suisse,
Zu¨rich, Switzerland, 2013.
[9] P. Nourjah, S. R. Ahmad, C. Karwoski, and M. Willy, “Es-
timates of acetaminophen (Paracetomal)-associated over-
doses in the United States,” Pharmacoepidemiology and Drug
Safety, vol. 15, no. 6, pp. 398–405, 2006.
[10] R. Williams, “Classiﬁcation, etiology, and considerations of
outcome in acute liver failure,” Seminars in Liver Disease,
vol. 16, no. 4, pp. 343–348, 1996.
[11] D. G. N. Craig, C. M. Bates, J. S. Davidson, K. G. Martin,
P. C. Hayes, and K. J. Simpson, “Overdose pattern and
outcome in paracetamol-induced acute severe hepatotoxic-
ity,” British Journal of Clinical Pharmacology, vol. 71, no. 2,
pp. 273–282, 2011.
[12] H. Kupferschmidt,Medienmitteilung, Tox Info Suisse, Zu¨rich,
Switzerland, 2016.
[13] K. E. Bizovi and M. J. Smilkstein, “Acetaminophen,” in
Goldfrank’s Toxicologic Emergencies, L. R. Goldfrank,
N. E. Flomenbaum, and N. A. Lewin, Eds., pp. 480–501,
McGraw-Hill, New York, NY, USA, 7th edition, 2002.
[14] G. P. Aithal, P. B. Watkins, R. J. Andrade et al., “Case deﬁ-
nition and phenotype standardization in drug-induced liver
injury,” Clinical Pharmacology & 1erapeutics, vol. 89, no. 6,
pp. 806–815, 2011.
[15] L. S. Friedman, Approach to the Patient with Abnormal Liver
Biochemical and Function Tests, UpToDate®, Waltham, MA,
USA, 2018.
[16] E. Goldberg and S. Chopra, Acute Liver Failure in Adults:
Etiology, Clinical Manifestations, and Diagnosis, UpToDate®,
Waltham, MA, USA, 2018.
[17] E. Walter, M. Duetz Schmucki, C. Bu¨rli et al., Sui-
zidpra¨vention in der Schweiz. Ausgangslage, Handlungsbedarf
und Aktionsplan.Bundesamt fu¨r Gesundheit (BAG), Ko¨niz,
Switzerland, 2016.
[18] T. Reisch, T. Steﬀen, A. Maillart, and K. Michel, Monitoring
des suizidalen Verhaltens in der Agglomeration Bern im
Rahmen der WHO/MONSUE Multicenter Study on Suicidal
6 Emergency Medicine International
Behaviour und des Berner Bu¨ndnisses gegen Depressionen,
Bundesamt fu¨r Gesundheit (BAG), Ko¨niz, Switzerland, 2009.
[19] D. Gunnell, V. Murray, and K. Hawton, “Use of paracetamol
(acetaminophen) for suicide and nonfatal poisoning:
worldwide patterns of use and misuse,” Suicide & Life-
1reatening Behavior, vol. 30, no. 4, pp. 313–326, 2000.
[20] C. Daly, E. Griﬃn, D. M. Ashcroft, R. T. Webb, I. J. Perry, and
E. Arensman, “Frequently used drug types and alcohol in-
volvement in intentional drug overdoses in Ireland: a national
registry study,” European Journal of Public Health, vol. 28,
no. 4, pp. 681–686, 2018.
[21] A. Mikhail, O. Tanoli, G. Le´gare´ et al., “Over-the-counter
drugs and other substances used in attempted suicide pre-
sented to emergency departments in Montreal, Canada,”
Crisis, vol. 40, no. 3, pp. 166–175, 2018.
[22] Swissmedic, AW-Merkblatt. Mustertext fu¨r Paracetamol.
Selbstmedikation Fachinformation, Swissmedic, Bern, Swit-
zerland, 2016.
[23] B. R. Morthorst, A. Erlangsen, M. Nordentoft, K. Hawton,
L. C. G. Hoegberg, and K. P. Dalhoﬀ, “Availability of para-
cetamol sold over the counter in europe: a descriptive cross-
sectional international survey of pack size restriction,” Basic &
Clinical Pharmacology & Toxicology, vol. 122, no. 6,
pp. 643–649, 2018.
[24] D. N. Bateman, “Pack size and paracetamol overdose: 16 years
later,” Clinical Toxicology, vol. 52, no. 8, pp. 821–823, 2014.
[25] K. Hawton, S. Simkin, J. J. Deeks et al., “Eﬀects of a drug
overdose in a television drama on presentations to hospital for
self poisoning: time series and questionnaire study,” BMJ,
vol. 318, no. 7189, pp. 972–977, 1999.
[26] W. M. Lee, “Acetaminophen-related acute liver failure in the
United States,”Hepatology Research, vol. 38, no. s1, pp. S3–S8,
2008.
[27] D. G. N. Craig, C. M. Bates, J. S. Davidson, K. G. Martin,
P. C. Hayes, and K. J. Simpson, “Staggered overdose pattern
and delay to hospital presentation are associated with adverse
outcomes following paracetamol-induced hepatotoxicity,”
British Journal of Clinical Pharmacology, vol. 73, no. 2,
pp. 285–294, 2012.
[28] C. Pezzia, C. Sanders, S. Welch, A. Bowling, and W. M. Lee,
“Psychosocial and behavioral factors in acetaminophen-re-
lated acute liver failure and liver injury,” Journal of Psycho-
somatic Research, vol. 101, pp. 51–57, 2017.
[29] L. C. Hawkins, J. N. Edwards, and P. I. Dargan, “Impact of
restricting paracetamol pack sizes on paracetamol poisoning
in the United Kingdom,” Drug Safety, vol. 30, no. 6,
pp. 465–479, 2007.
[30] P. N. Newsome, A. J. Bathgate, N. C. Henderson et al.,
“Referral patterns and social deprivation in paracetamol-in-
duced liver injury in Scotland,”1e Lancet, vol. 358, no. 9293,
pp. 1612-1613, 2001.
Emergency Medicine International 7
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
